Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Clearmind Medicine Inc.

< Previous 1 2 3 Next >
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND SPRC
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND PLRZ
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND SPRC
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Shareholders Meeting Results
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND SPRC
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.